Our Science

We own a proprietary platform technology targeting aging, inflammation and senescence, focused at delivering a therapeutic gene that has demonstrated strong clinical efficacy and safety in treating cardiovascular, pulmonary and orthopedic conditions.

We have recently reached an exclusive license agreement with the Icahn School of Medicine at Mount Sinai in New York, NY to a broad patent portfolio related to Sphingolipids metabolizing enzyme (SME) and its therapeutic application in senescence, inflammation and aging. This high value technology has been developed in the lab of Efrat Eliyahu, PhD, Assistant Professor of Genetics and Genomics Sciences at Icahn Mount Sinai, and is addressing acute and chronic inflammatory diseases and related conditions. The therapeutic protein is administered as gene therapy via using adeno-associated-virus mediated delivery. Icahn Mount Sinai will continue to partner with Gromit to support Gromit-funded research and clinical efforts that leverage Icahn Mount Sinai’s extraordinary expertise and facilities.

Our technology is also supported by multiple peer reviewed publications, clinical and scientific collaborations and NIH grants.

Selected Publications